Rapid second-tier testing for newborn screening and therapeutic monitoring of maple syrup urine disease

2014 ◽  
Vol 47 (15) ◽  
pp. 149-150
Author(s):  
Graham Sinclair ◽  
Clara van Karnebeek ◽  
Ramona Salvarinova ◽  
Gloria Ho ◽  
Keiko Ueda ◽  
...  
2021 ◽  
Vol 7 (2) ◽  
pp. 25
Author(s):  
Mona Sajeev ◽  
Sharon Chin ◽  
Gladys Ho ◽  
Bruce Bennetts ◽  
Bindu Parayil Sankaran ◽  
...  

Maple syrup urine disease is caused by a deficiency of branched-chain alpha-ketoacid dehydrogenase, responsible for degradation of leucine, isoleucine, and valine. Biallelic pathogenic variants in BCKDHA, BCKDHB, or DBT genes result in enzyme deficiency. We report the case of a female infant who presented with mild gross motor delay at 4 months, and seizures with hypoglycaemia at 5 months. Newborn screening returned total leucine/isoleucine at the 99.5th centile of the population; however, as second-tier testing reported minimal alloisoleucine, the results were considered inconsistent with MSUD. Plasma amino acid and urine organic acid analyses at 5 months were, however, consistent with a diagnosis of MSUD. A brain MRI showed bilateral symmetrical T2 hyperintense signal abnormalities involving white matter, globus pallidus, thalamus, brainstem, and dentate nuclei with restricted diffusion. A repeat MRI 10 months post-dietary-intervention showed the resolution of these changes and progression in myelination. Her clinical phenotype, including protein tolerance, correlated with intermediate MSUD. Molecular analysis of all three genes identified two variants of uncertain significance, c.434-15_434-4del and c.365A>G (p. Tyr122Cys) in the DBT gene. The rate of leucine decarboxylation in fibroblasts was reduced, but not to the extent observed in classical MSUD patients, supporting an intermediate form of MSUD. Previously reported mRNA splicing studies supported a deleterious effect of the c.434-15_434-4del variant. This functional evidence and confirmation that the variants were in trans, permitted their reclassification as pathogenic and likely pathogenic, respectively, facilitating subsequent prenatal testing. This report highlights the challenges in identifying intermediate MSUD by newborn screening, reinforcing the importance of functional studies to confirm variant pathogenicity in this era of molecular diagnostics.


2008 ◽  
Vol 54 (3) ◽  
pp. 542-549 ◽  
Author(s):  
Devin Oglesbee ◽  
Karen A Sanders ◽  
Jean M Lacey ◽  
Mark J Magera ◽  
Bruno Casetta ◽  
...  

Abstract Background: Newborn screening for maple syrup urine disease (MSUD) relies on finding increased concentrations of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine by tandem mass spectrometry (MS/MS). d-Alloisoleucine (allo-Ile) is the only pathognomonic marker of MSUD, but it cannot be identified by existing screening methods because it is not differentiated from isobaric amino acids. Furthermore, newborns receiving total parenteral nutrition often have increased concentrations of BCAAs. To improve the specificity of newborn screening for MSUD and to reduce the number of diet-related false-positive results, we developed a LC-MS/MS method for quantifying allo-Ile. Methods: Allo-Ile and other BCAAs were extracted from a 3/16-inch dried blood spot punch with methanol/H2O, dried under nitrogen, and reconstituted into mobile phase. Quantitative LC-MS/MS analysis of allo-Ile, its isomers, and isotopically labeled internal standards was achieved within 15 min. To determine a reference interval for BCAAs including allo-Ile, we analyzed 541 dried blood spots. We also measured allo-Ile in blinded samples from 16 MSUD patients and 21 controls and compared results to an HPLC method. Results: Intra- and interassay imprecision (mean CVs) for allo-Ile, leucine, isoleucine, and valine ranged from 1.8% to 7.4%, and recovery ranged from 91% to 129%. All 16 MSUD patients were correctly identified. Conclusions: The LC-MS/MS method can reliably measure allo-Ile in dried blood spots for the diagnosis of MSUD. Applied to newborn screening as a second-tier test, it will reduce false-positive results, which produce family anxiety and increase follow-up costs. The assay also appears suitable for use in monitoring treatment of MSUD patients.


Screening ◽  
1992 ◽  
Vol 1 (1) ◽  
pp. 49-62 ◽  
Author(s):  
Akihiro Yamaguchi ◽  
Yoshikiyo Mizushima ◽  
Masaru Fukushi ◽  
Yoshio Shimizu ◽  
Yuko Kikuchi ◽  
...  

2010 ◽  
Vol 100 (2) ◽  
pp. 136-142 ◽  
Author(s):  
R.L. Puckett ◽  
F. Lorey ◽  
P. Rinaldo ◽  
M.H. Lipson ◽  
D. Matern ◽  
...  

2016 ◽  
Vol 8 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Leniza G. De Castro-Hamoy ◽  
Mary Anne D. Chiong ◽  
Sylvia C. Estrada ◽  
Cynthia P. Cordero

2006 ◽  
Vol 29 (4) ◽  
pp. 586-586 ◽  
Author(s):  
K. Bhattacharya ◽  
V. Khalili ◽  
V. Wiley ◽  
K. Carpenter ◽  
B. Wilcken

2008 ◽  
Vol 54 (10) ◽  
pp. 1739-1741 ◽  
Author(s):  
Ralph Fingerhut ◽  
Eva Simon ◽  
Esther M Maier ◽  
Julia B Hennermann ◽  
Udo Wendel

Sign in / Sign up

Export Citation Format

Share Document